| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(7 years from now) | |
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(11 years from now) | |
Accrufer is owned by Shield Tx.
Accrufer contains Ferric Maltol.
Accrufer has a total of 3 drug patents out of which 0 drug patents have expired.
Accrufer was authorised for market use on 25 July, 2019.
Accrufer is available in capsule;oral dosage forms.
Accrufer can be used as method of treating iron deficiency.
Drug patent challenges can be filed against Accrufer from 2023-07-26.
The generics of Accrufer are possible to be released after 23 October, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 25, 2024 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 2023-07-26
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE;ORAL
ACCRUFER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic